Page last updated: 2024-09-03

muramylnac-ala-isogln-lys-tripeptide and ifosfamide

muramylnac-ala-isogln-lys-tripeptide has been researched along with ifosfamide in 1 studies

Compound Research Comparison

Studies
(muramylnac-ala-isogln-lys-tripeptide)
Trials
(muramylnac-ala-isogln-lys-tripeptide)
Recent Studies (post-2010)
(muramylnac-ala-isogln-lys-tripeptide)
Studies
(ifosfamide)
Trials
(ifosfamide)
Recent Studies (post-2010) (ifosfamide)
50415,0451,4301,113

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bernstein, ML; Betcher, D; Conrad, E; Ferguson, W; Gebhardt, M; Goorin, AM; Grier, H; Harris, MB; Healey, J; Huvos, A; Kleinerman, ES; Krailo, M; Link, M; Meyers, PA; Montebello, J; Nadel, H; Nieder, M; Sato, J; Schwartz, CL; Siegal, G; Weiner, M; Wells, R; Wold, L; Womer, R1

Trials

1 trial(s) available for muramylnac-ala-isogln-lys-tripeptide and ifosfamide

ArticleYear
Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Mar-20, Volume: 23, Issue:9

    Topics: Acetylmuramyl-Alanyl-Isoglutamine; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Preschool; Cisplatin; Disease-Free Survival; Doxorubicin; Female; Humans; Ifosfamide; Infant; Male; Methotrexate; Osteosarcoma; Prospective Studies

2005